Skip to main content
Fig. 4 | Orphanet Journal of Rare Diseases

Fig. 4

From: Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany

Fig. 4

AEs by MedDRA System Organ Class. Safety analysis was based on 111 patients who received at least one dose of risdiplam (31 patients with SMA1 and 80 patients with SMA2). Percentages are based on the total number of events (30 and 100 AEs in SMA 1 and SMA2, respectively). AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities; SMA1, spinal muscular atrophy type 1; SMA2, spinal muscular atrophy type 2

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172